OFM studies reduce costs by providing a complete pharmacological profile early in drug development.
OFM probes enable continuous sampling from clearly specified tissue types.
OFM samples all substances from the interstitial fluid independent of size, lipophilicity or protein-binding.
Latest News
Dr Thomas Birngruber and Dr Frank Sinner will present valuable insights on improved formulation screening and local dermal PK and PD using dOFM sampling.
This webinar will give you a concise overview of dOFM capabilities and introduce possible setups for preclinical and clinical studies. We will present several case studies for drug development, biomarker discovery and bioequivalence assessment. More information
Our experts will answer all your questions personally, such as:
- How can dOFM improve your dermal drug development?
- How to monitor local drug concentration in the dermis?
- How to perform a head to head comparison of formulations in the same subject?
- How to translate preclinical results directly into the clinical situation?
Date: November 10, 2020
Time: 3:00 pm London / 10:00 am New York
Duration: 60 Minutes
FDA Video: The U.S. Food and Drug Administration recently published a video showing the potential of dermal open flow microperfusion (dOFM) for generic drug development.
Contact Us
Please reach out and we will answer
your questions, react to your ideas and
deal with your requirements.
Keep in touch
